Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

As PSA testing recommendations change and the debate surrounding testing continues, people with a high-risk of prostate cancer and their families need to stay informed. John Salata says he is grateful ...

For decades, it has been known that prostate specific antigen ‒ or PSA ‒ tests are a flawed way to diagnose prostate cancer. Many men have a high PSA without having cancer. Others have low PSA that ...

Rishi Sunak has urged men to be checked for prostate cancer as part of a new screening drive. The former prime minister has given his backing to an initiative run by the charity P ...

To date, men undergoing screening through the measurement of prostate-specific antigen (PSA) levels have had a significant reduction in neoplastic mortality. Because of its low specificity, however, ...

Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological explanation.

A new at-home saliva test for prostate cancer could outperform current testing methods, a new study suggests. Researchers have developed a simple spit test, that can be performed at home and does not ...

A representative for former President Joe Biden said he last took a prostate-specific antigen blood test, commonly used to screen for prostate cancer, in 2014. Although the exact date of the test wasn ...

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...